Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_assertion type Assertion NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_head.
- NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_assertion description "[The data in this study of a large number of cancer patients receiving intravenous bisphosphonates suggest that MHC class II polymorphisms represent genetic risk factors for the development of ARONJ.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_provenance.
- NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_assertion evidence source_evidence_literature NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_provenance.
- NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_assertion SIO_000772 23218978 NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_provenance.
- NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_assertion wasDerivedFrom befree-20150227 NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_provenance.
- NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_assertion wasGeneratedBy ECO_0000203 NP458628.RAUew4ySfd9NyWelGVsbrmL11VhcVfhK87AAMok4YzLpg130_provenance.